دورية أكاديمية
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH -Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors.
| العنوان: | Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH -Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. |
|---|---|
| المؤلفون: | Lapin M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway., Huang HJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Chagani S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Javle M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Shroff RT; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Division of Hematology/Oncology, University of Arizona Cancer Center, Tucson, AZ., Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Raina A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Madwani K; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Holley VR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Call SG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Dustin DJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Lanman RB; Guardant Health, Redwood City, CA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Raymond VM; Guardant Health, Redwood City, CA., Kwong LN; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX. |
| المصدر: | JCO precision oncology [JCO Precis Oncol] 2022 Feb; Vol. 6, pp. e2100197. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2017]- |
| مواضيع طبية MeSH: | Bile Duct Neoplasms*/blood , Bile Duct Neoplasms*/drug therapy , Bile Duct Neoplasms*/enzymology , Bile Duct Neoplasms*/genetics , Cholangiocarcinoma*/blood , Cholangiocarcinoma*/drug therapy , Cholangiocarcinoma*/enzymology , Cholangiocarcinoma*/genetics , Circulating Tumor DNA*/blood , Circulating Tumor DNA*/genetics , Enzyme Inhibitors*/pharmacology , Isocitrate Dehydrogenase*/antagonists & inhibitors, Bile Ducts, Intrahepatic ; Clonal Evolution ; Humans ; Prognosis |
| مستخلص: | Purpose: IDH mutations occur in about 30% of patients with cholangiocarcinoma. Analysis of mutations in circulating tumor DNA (ctDNA) can be performed by droplet digital polymerase chain reaction (ddPCR). The analysis of ctDNA is a feasible approach to detect IDH mutations. Methods: We isolated ctDNA from the blood of patients with IDH -mutated advanced cholangiocarcinoma collected at baseline, on therapy, and at progression to isocitrate dehydrogenase (IDH) inhibitors. Results: Of 31 patients with IDH1 R132 (n = 26) or IDH2 R172 mutations (n = 5) in the tumor, IDH mutations were detected in 84% of ctDNA samples analyzed by ddPCR and in 83% of ctDNA samples analyzed by next-generation sequencing (NGS). Patients with a low variant allele frequency of ctDNA detected by NGS at baseline had a longer median time to treatment failure compared to patients with high variant allele frequency of ctDNA (3.6 v 1.5 months; P = .008). Patients with a decrease in IDH -mutated ctDNA on therapy by ddPCR compared with no change/increase had a trend to a longer median survival ( P = .07). Most frequent emergent alterations in ctDNA by NGS at progression were ARID1A (n = 3) and TP53 mutations (n = 3). Conclusion: Detection of IDH mutations in ctDNA in patients with advanced cholangiocarcinoma is feasible, and dynamic changes in ctDNA can correspond with the clinical course and clonal evolution. Competing Interests: Milind JavleHonoraria: QED Therapeutics, Incyte, TransThera Biosciences, Merck, EMD Serono/Merck, AstraZeneca/MedImmuneConsulting or Advisory Role: QED Therapeutics, OncoSil, Incyte, Mundipharma EDO GmbH, AstraZeneca, Merck, EMD Serono, DerazantinibOther Relationship: Rafael Pharmaceuticals, Incyte, Pieris Pharmaceuticals, Merck, Merck Serono, Novartis, Seattle Genetics, BeiGene, QED Therapeutics, Bayer Rachna T. ShroffConsulting or Advisory Role: Exelixis, Merck, QED Therapeutics, Incyte, AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Servier, Genentech, Basilea, Helsinn TherapeuticsSpeakers' Bureau: Servier, Helsinn TherapeuticsResearch Funding: Pieris Pharmaceuticals, Taiho Pharmaceutical, Merck, Exelixis, QED Therapeutics, Rafael Pharmaceuticals, Bristol Myers Squibb, Bayer, Immunovaccine, Seattle Genetics, Novocure, Nucana, Loxo/Lilly Shubham PantHonoraria: 4D PharmaConsulting or Advisory Role: Xencor, Zymeworks, IpsenResearch Funding: Mirati Therapeutics (Inst), Lilly (Inst), RedHill Biopharma (Inst), Xencor (Inst), Five Prime Therapeutics (Inst), Novartis (Inst), Rgenix (Inst), Sanofi/Aventis (Inst), ArQule (Inst), Bristol Myers Squibb (Inst), Onco Response (Inst), GlaxoSmithKline (Inst), Ipsen (Inst), Astellas Pharma (Inst), Purple Biotech (Inst), 4D Pharma (Inst), Boehringer Ingelheim (Inst), NGM Biopharmaceuticals (Inst), Janssen (Inst), Arcus Biosciences (Inst), Elicio Therapeutics (Inst) S. Greg CallEmployment: Tempus Richard B. LanmanEmployment: Guardant HealthLeadership: Guardant Health, Biolase, Circulogene TheranosticsStock and Other Ownership Interests: Guardant Health, Biolase, Forward, Circulogene, Teiko Bio, Inc, Glympse BioConsulting or Advisory Role: Forward, Guardant Health, Glympse Bio, Teiko Bio, IncResearch Funding: Guardant Health Funda Meric-BernstamEmployment: MD Anderson Cancer CenterHonoraria: Rutgers Cancer Institute of New JerseyConsulting or Advisory Role: Samsung Bioepis, Xencor, Debiopharm Group, Silverback Therapeutics, IBM Watson Health, Roche, PACT Pharma, eFFECTOR Therapeutics, Kolon Life Sciences, Tyra Biosciences, Zymeworks, Puma Biotechnology, Zentalis, Alkermes, Infinity Pharmaceuticals, AbbVie, Black Diamond Therapeutics, Eisai, OnCusp Therapeutics, Lengo Therapeutics, Tallac Therapeutics, Karyopharm Therapeutics, BiovicaSpeakers' Bureau: Chugai PharmaResearch Funding: Novartis (Inst), AstraZeneca (Inst), Taiho Pharmaceutical (Inst), Genentech (Inst), Calithera Biosciences (Inst), Debiopharm Group (Inst), Bayer (Inst), Aileron Therapeutics (Inst), PUMA Biotechnology (Inst), CytomX Therapeutics (Inst), Jounce Therapeutics (Inst), Zymeworks (Inst), Curis (Inst), Pfizer (Inst), eFFECTOR Therapeutics (Inst), AbbVie (Inst), Boehringer Ingelheim (I), Guardant Health (Inst), Daiichi Sankyo (Inst), GlaxoSmithKline (Inst), Seattle Genetics (Inst), Klus Pharma (Inst), Takeda (Inst)Travel, Accommodations, Expenses: Beth Israel Deaconess Medical Center Victoria M. RaymondEmployment: Guardant HealthStock and Other Ownership Interests: Guardant Health, Trovagene Lawrence N. KwongStock and Other Ownership Interests: Sarepta TherapeuticsResearch Funding: Array BioPharma Filip JankuStock and Other Ownership Interests: Cardiff OncologyConsulting or Advisory Role: Deciphera, Novartis, Sequenom, Foundation Medicine, Guardant Health, Synlogic, Valeant/Dendreon, IFM Therapeutics, Sotio, PureTech, Jazz Pharmaceuticals, Immunomet, IDEAYA Biosciences, Cardiff OncologyResearch Funding: Novartis (Inst), BioMed Valley Discoveries (Inst), Roche (Inst), Agios (Inst), Astellas Pharma (Inst), Deciphera (Inst), Plexxikon (Inst), Piqur (Inst), Fujifilm (Inst), Symphogen (Inst), Bristol Myers Squibb (Inst), Asana Biosciences (Inst), Astex Pharmaceuticals (Inst), Genentech (Inst), Proximagen (Inst)Other Relationship: Bio-RadNo other potential conflicts of interest were reported. |
| References: | Clin Cancer Res. 2017 Jul 15;23(14):3657-3666. (PMID: 28096270) Lancet Oncol. 2020 Jun;21(6):796-807. (PMID: 32416072) Clin Cancer Res. 2016 Feb 1;22(3):567-74. (PMID: 26446943) Ann Oncol. 2017 Mar 1;28(3):642-650. (PMID: 27993791) Cancer Discov. 2015 Oct;5(10):1040-8. (PMID: 26109333) PLoS One. 2015 Oct 16;10(10):e0140712. (PMID: 26474073) Mol Cancer Ther. 2016 Jun;15(6):1397-404. (PMID: 27207774) Int J Cancer. 2021 Feb 1;148(3):702-712. (PMID: 32700810) Sci Rep. 2019 Sep 13;9(1):13261. (PMID: 31519967) J Clin Oncol. 2020 Oct 10;38(29):3398-3406. (PMID: 32530764) Discov Med. 2016 May;21(117):373-80. (PMID: 27355333) Expert Rev Mol Diagn. 2015;15(12):1631-44. (PMID: 26559503) Clin Cancer Res. 2018 Aug 1;24(15):3539-3549. (PMID: 29691297) Cancer Discov. 2018 Dec;8(12):1540-1547. (PMID: 30355724) J Clin Oncol. 2020 May 20;38(15):1693-1701. (PMID: 32208957) Blood. 2017 Aug 10;130(6):722-731. (PMID: 28588020) Sci Transl Med. 2017 Feb 1;9(375):. (PMID: 28148839) Cancer. 2016 Dec 15;122(24):3838-3847. (PMID: 27622582) Cancer Discov. 2015 Jul;5(7):752-67. (PMID: 26069190) Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. (PMID: 29848569) N Engl J Med. 2018 Jun 21;378(25):2386-2398. (PMID: 29860938) |
| معلومات مُعتمدة: | P30 CA016672 United States CA NCI NIH HHS; UL1 TR003167 United States TR NCATS NIH HHS |
| المشرفين على المادة: | 0 (Circulating Tumor DNA) 0 (Enzyme Inhibitors) EC 1.1.1.41 (Isocitrate Dehydrogenase) |
| تواريخ الأحداث: | Date Created: 20220216 Date Completed: 20220404 Latest Revision: 20240214 |
| رمز التحديث: | 20240214 |
| مُعرف محوري في PubMed: | PMC8865526 |
| DOI: | 10.1200/PO.21.00197 |
| PMID: | 35171660 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2473-4284 |
|---|---|
| DOI: | 10.1200/PO.21.00197 |